<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Depending on the active ingredient or drug compound of interest, the type of formulation required (e.g., selection of suitable coating material for desired release profile), and the morphology of the final encapsulated product, it is possible to modify the configuration of the supercritical fluid system to perform different processes, as shown in our earlier studies where experiments for SAS [
 <xref rid="B10-pharmaceutics-11-00021" ref-type="bibr" class="xref">10</xref>,
 <xref rid="B11-pharmaceutics-11-00021" ref-type="bibr" class="xref">11</xref>,
 <xref rid="B20-pharmaceutics-11-00021" ref-type="bibr" class="xref">20</xref>], SAS with enhanced mass transfer (SAS-EM) [
 <xref rid="B10-pharmaceutics-11-00021" ref-type="bibr" class="xref">10</xref>], supercritical foaming [
 <xref rid="B12-pharmaceutics-11-00021" ref-type="bibr" class="xref">12</xref>,
 <xref rid="B13-pharmaceutics-11-00021" ref-type="bibr" class="xref">13</xref>,
 <xref rid="B14-pharmaceutics-11-00021" ref-type="bibr" class="xref">14</xref>,
 <xref rid="B21-pharmaceutics-11-00021" ref-type="bibr" class="xref">21</xref>], and supercritical drying [
 <xref rid="B22-pharmaceutics-11-00021" ref-type="bibr" class="xref">22</xref>] were performed with a custom-built supercritical fluid system.
</p>
